Clinical Trials - RMTI

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT05110768Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion TherapyUNKNOWNPHASE22021-11-302022-05-302022-04-30
NCT04689932Triferic AVNU Infusion Via Freedom Pump During HemodialysisCOMPLETEDPHASE42021-04-192021-06-192021-06-19
NCT04239391Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)UNKNOWNPHASE32020-09-012023-11-012023-08-31
NCT04409132Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.COMPLETEDPHASE1, PHASE22020-06-252021-04-022021-04-02
NCT04042324A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis PatientsCOMPLETEDPHASE1, PHASE22019-09-302020-01-162020-01-16
NCT03303144Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD PatientsCOMPLETEDPHASE1, PHASE22017-10-012017-12-282017-12-28
NCT02905981Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) ProtocolTERMINATEDPHASE22017-01-172018-03-152018-03-15
NCT02909153Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal DialysisCOMPLETEDPHASE12017-012017-072017-07
NCT02739100Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD PatientsCOMPLETEDPHASE12016-042016-072016-07
NCT02767128Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy VolunteersCOMPLETEDPHASE12016-042016-042016-04
NCT02595437Triferic Pediatric Pharmacokinetic ProtocolCOMPLETEDPHASE1, PHASE22015-11-012017-012016-12
NCT02636049Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult VolunteersCOMPLETEDPHASE12015-102015-102015-10
NCT01894906Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD PatientsCOMPLETEDPHASE1, PHASE22013-072013-092013-09
NCT01920854A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.COMPLETEDPHASE12013-062013-092013-09
NCT01503021Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic HemodialysisCOMPLETEDPHASE32011-112014-012014-01
NCT01322347Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)COMPLETEDPHASE32011-042014-022014-01
NCT01320202Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis PatientsCOMPLETEDPHASE32011-032013-112013-05
NCT01286012Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis PatientsCOMPLETEDPHASE22011-012013-012013-01
NCT00548249Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic HemodialysisCOMPLETEDPHASE22007-082010-012009-10